Luminex Zika Test Granted FDA Emergency Use Authorization | GenomeWeb

NEW YORK (GenomeWeb) – The US Food and Drug Administration has granted Emergency Use Authorization for a Zika assay from Luminex, the firm announced today.

The test, called the xMAP MultiFLEX Zika RNA Assay, was designed by Luminex partner GenArraytion, a Rockville, Maryland-based diagnostics maker. The xMAP test is authorized to detect viral RNA in blood or serum, as well as urine samples collected and tested in conjunction with blood or serum. It will be provided to labs that are CLIA certified to run highly complex tests.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.

Mar
02
Sponsored by
VelaDx

This online seminar will highlight recent advances in the use of next-generation sequencing to detect drug-resistant mutations in patients with HIV or HCV.